Track every registration update on the InsiderAlpha IPO tracker.
Updated Jul 16, 2026 · Last SEC filing 2026-07-10
Aktis Oncology, Inc. (AKTS) has filed 2 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-10. 1 Form 8-K material event filings were reported by AKTS in the last 90 days. 2 Form 144 notices of proposed sale were filed for AKTS stock. InsiderAlpha tracks every AKTS SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SEC CIK | 0002035832 |
|---|
| Form 4 filings (90d) | 2 |
|---|---|
| Form 8-K filings (90d) | 1 |
| Form 144 notices (90d) | 2 |
| Latest Form 4 filing | 2026-07-10 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Czibere Akos | Chief Medical Officer | S — Open-market sale | 30.8K | $27.95 | $862K | SEC | |
| Ron-Bigger Shulamit | Chief Operating Officer | S — Open-market sale | 4.2K | $28.75 | $121K | SEC | |
| Ron-Bigger Shulamit | Chief Operating Officer | S — Open-market sale | 30.0K | $27.94 | $838K | SEC | |
| Czibere Akos | Chief Medical Officer | S — Open-market sale | 14.8K | $27.13 | $401K | SEC | |
| Czibere Akos | Chief Medical Officer | S — Open-market sale | 4.4K | $28.71 | $125K | SEC | |
| Czibere Akos | Chief Medical Officer | M — Option exercise | 50.0K | $4.95 | $248K | SEC | |
| Ron-Bigger Shulamit | Chief Operating Officer | M — Option exercise | 50.0K | $3.66 | $183K | SEC | |
| Ron-Bigger Shulamit | Chief Operating Officer | S — Open-market sale | 15.8K | $27.13 | $429K | SEC | |
| Kim Helen Susan | Insider | J — Other acquisition / disposition | 134.8K | — | — | SEC | |
| EcoR1 Capital, LLC | Director | J — Other acquisition / disposition | 128.5K | — | — | SEC | |
| Kim Helen Susan | Insider | P — Open-market purchase | 812.5K | $18.00 | $14.62M | SEC | |
| EcoR1 Capital, LLC | Director | P — Open-market purchase | 2.08M | $18.00 | $37.40M | SEC | |
| EcoR1 Capital, LLC | Director | P — Open-market purchase | 144.4K | $18.00 | $2.60M | SEC | |
| Foley Todd | Insider | J — Other acquisition / disposition | 597.4K | — | — | SEC | |
| Vida Ventures II, LLC | Insider | J — Other acquisition / disposition | 134.8K | — | — | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Aktis Oncology, Inc. (AKTS). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Ron-Bigger Shulamit | 5 | $1.57M |
| Czibere Akos | 5 | $1.64M |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in AKTS insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live AKTS dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.